


TUMOR BOARD: How The Experts Approach Personalized Care Plans in **ER-POSITIVE BREAST CANCER**



3 May 2022

11:30 – 12:30 CEST

Hamburg Hall, Hub27, Berlin

LEARNING OBJECTIVES

- Explain how recent evidence can be applied to treatment or considered in the context of evolving care paradigms in the management of HR+/HER2- breast cancer
- Determine tumor and patient characteristics in parallel with clinical trial evidence and guidelines to personalize treatment for patients with HR+/HER2- breast cancer
- Summarize safety and efficacy data from clinical trials that evaluated new agents for HR+/HER2- breast cancer, including oral selective estrogen receptor degraders, in the context of unmet needs in the field and evolving treatment paradigms

PROGRAM CHAIR



Fatima Cardoso, MD

Director Breast Unit
Champalimaud Clinical Center
Lisbon, Portugal

FACULTY



Mario Campone, MD, PhD

Chief Executive Officer
Institut de Cancérologie de l'Ouest (ICO)
Angers, France



Giuseppe Viale, MD, FRCPath

Chairman
Department of Pathology
University of Milan
Milan, Italy

AGENDA

11:30 – 11:35 CEST	Introductions	Fatima Cardoso, MD
Tumor Board 1		
11:35 – 11:50 CEST	Current Management Options for HR+/HER2- Metastatic Breast Cancer	Fatima Cardoso, MD
11:50 – 12:00 CEST	Investigating Novel Therapeutic Approaches	Giuseppe Viale, MD, FRCPath
Tumor Board 2		
12:00 – 12:20 CEST	Evolving Management Paradigms for High-Risk Early-Stage HR+/HER2- Breast Cancer	Mario Campone, MD, PhD
12:20 – 12:25 CEST	Post-session Questions	Fatima Cardoso, MD
12:25 – 12:30 CEST	Conclusions	Fatima Cardoso, MD

This activity is supported by an educational grant from Sanofi Genzyme.